Table 2 Evidence supporting BRRM for women with BRCA mutations
First author | Year | Total patients in cohort study | BRCA1 patients | BRCA2 patients | Total number of BRRM patients | BRCA1 in BRRM | BRCA2 in BRRM | Median follow-up (year) | Development of BC (%) | RR (95% CI) | HR of all-cause mortality (95% CI) | HR of BC-specific mortality (95%CI) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sarah L Ingham | 2013 | 691 | 346 | 345 | 126 | 71 | 55 | - | 3% | 0.11 (0.04-0.32) | 0.25 (0.03-1.81) | 0.29 (0.03-2.61) |
B.A.M. Heemskerk-Gerritsen | 2013 | 570 | 405 | 165 | 216 | 156 | 56 | 8.5 | 0 | 0.02 (0.00-0.33) | 0.2 (0.02-1.68) | - |
Hanne Meijers-Heijboer | 2001 | 139 | 120 | 19 | 76 | 64 | 12 | 3 | 0 | 0.1 (0.01-1.42) | - | - |
Susan M Domchek | 2010 | 1619 | 1032 | 587 | 257 | 159 | 88 | 3.65 | 0 | 0.12 (0.01-1.87) | - | - |
Skytte AB | 2011 | 307 | 201 | 106 | 96 | 67 | 29 | - | 0.80% | 0.49 (0.17-1.4) | - | - |